Teriparatide oral - Emisphere Technologies/Novartis

Drug Profile

Teriparatide oral - Emisphere Technologies/Novartis

Alternative Names: Parathyroid-hormone-1-34-oral; PTH-1-34-oral-Emisphere-Technologies-Novartis; PTH1-34

Latest Information Update: 24 Jun 2011

Price : $50

At a glance

  • Originator Emisphere Technologies
  • Developer Novartis
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Jun 2011 Discontinued - Phase-I for Postmenopausal osteoporosis in Denmark (PO)
  • 17 Jun 2011 Discontinued - Phase-I for Postmenopausal osteoporosis in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top